New research reveals that patients who come off new GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight far faster than those who end conventional diet and exercise regimens.
Findings released in a prominent health publication shows that while overweight individuals frequently drop a large proportion of their total mass while on the medication, the weight returns at an average rate of 0.8 kg per month once they quit.
"People buying these medications must be aware of the risk of quick weight regain when the treatment concludes," stated expert Dr. Susan Jebb.
Such speed of recovery implies a return to original mass within about a year and a half.
Analyzing Approaches
The analysis, which looked at 37 of studies involving thousands of patients, compared the results of these new drugs with conventional dieting.
Researchers point out that individuals who lose weight through dieting usually see a more gradual creep back—approximately 100 grams monthly—once they finish.
The Reason for the Quick Regain
Nutrition scientists suggest the mode of action of the jabs is key to understanding the heightened rebound.
The injections copy a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Sustained high doses of GLP-1 concentrations several times higher than normal might result in the system to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its actions," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this GLP-1 'fix' leads to hunger is unsuppressed, making overeating much more probable."
A Chronic Issue?
Health authorities suggest the injections for people with weight-linked health risks, accompanied by prescribed lifestyle changes.
Professionals contend that, given the significant potential of weight regain, the treatment might need to be long-term.
This perspective is supported by pharmaceutical companies, who say that the findings "emphasize the long-term nature of obesity," comparing it to managing diseases like diabetes.
Patient Accounts
Individuals who have discontinued the jabs report a sudden resurgence of appetite.
"It felt as if something that goes on and you become extremely hungry," described an individual.
The struggle is compounded if users have not established permanent dietary or behavioural modifications during therapy.
Widespread Interest
Recent estimates indicate that millions of people in the UK have used these injections in the past year, with desire being substantial.
- Adoption is greater among women than men.
- The middle-aged demographic shows the greatest usage rates.
- Many obtain the drugs through private prescriptions rather than the NHS.
In conclusion, clinicians emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a magic fix and long-term success relies on ongoing lifestyle changes.
